The briefing
Researchers developed an organoid-on-a-chip platform that pairs stem cell–derived brain organoids with a gold nanoplasmonic sensor to track Parkinson’s treatment effects in real time. The approach could speed drug screening and support more personalized therapy research.
Original headline
Gold nanoplasmonic chip tracks L-DOPA response in Parkinson's 'mini-brains'